Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.

Wu, Si-Han; Bi, Jun-Feng; Cloughesy, Timothy; Cavenee, Webster K; Mischel, Paul S

Wu, Si-Han; Bi, Jun-Feng; Cloughesy, Timothy; Cavenee, Webster K; Mischel, Paul S.

Afiliação

Wu SH; 1 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.
Bi JF; 1 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.
Cloughesy T; 1 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.
Cavenee WK; 1 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.
Mischel PS; 1 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.

Cancer Biol Med ; 11(4): 255-63, 2014 Dec.

Article em En | MEDLINE | ID: mdl-25610711

Palavras-chave

Glioblastoma; PI3K; Warburg effect; mTOR; mTORC2; metabolic reprogramming

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Biol Med Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos